Posted by Michael Wonder on 28 Jul 2020
Dr. Reddy's Laboratories received approval of Xeglyze (abametapir) 0.74% lotion in the U.S.
27 July 2020 - Dr. Reddy’s Laboratories today announced approval of Xeglyze (abametapir) 0.74% topical lotion, new drug application by the U.S. FDA.
The approval triggers the contractual pre-commercialisation milestone of $20 million payable to Hatchtech.
Xeglyze is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The company is working to commercialise this product through partners.
